Episode description
Episode description
Join us for an insightful interview with Prof Bruno Paiva from Clinical University of Navarra in Pamplona, Spain, as he and our host Dr. Isabel Olivera-Martinez, discuss the latest technical approaches to improving monitoring, risk stratification and differential diagnosis of patients with monoclonal gammopathies including MGUS (monoclonal gammopathy of unknown significance), smoldering myeloma and multiple myeloma.
Prof Paiva begins by highlighting the importance of developing less invasive tools to assess MRD, given that multiple myeloma patients are living longer and need to be monitored multiple times.
He further describes the potential updates to the guidelines of the International Myeloma Working Group that may include the use of mass spectrometry, as a more sensitive method to quantify the M-component as well as the application of next-generation techniques - such as next-generation flow cytometry and next-generation sequencing- to monitor disease in peripheral blood, as a complement to bone marrow assessments.
Prof Paiva also discusses the two largest ongoing translational studies, which aim to elucidate the “unknown” and define the clinical significance of MGUS and smoldering myeloma for each individual patient.
Host: Isabel Olivera-Martinez, PhD, Medical Writer
Guest: Prof Bruno Paiva
Learn More
What did you think of this podcast? Share your opinions with us in this short feedback survey.
Would you like to explore more eLearning or podcasts? Please visit the EHA Campus.
Subscribe, share, and review this podcast to be able to address topics you enjoy and like to listen to.
Follow EHA on Instagram: https://www.instagram.com/EHA_Hematology/
Facebook: https://e-h-a.link/facebook
LinkedIn: https://www.linkedin.com/company/eha/
Email us: education@ehaweb.org
Subscribe to receive the EHA Educational Updates via https://eha.news/subscribe